Not on a standard opiate panel. Standard urine drug test cups and dip cards, including 5, 10, and 12 panel formats, use immunoassay antibodies built to react with morphine, codeine, and closely related compounds such as hydrocodone and oxycodone. Tramadol's chemical structure differs enough from that morphine class that it does not reliably trigger a positive opiate result. Gabapentin is not an opioid at all, so it was never part of a standard opiate panel to begin with. Catching either drug requires a dedicated immunoassay or laboratory confirmation.
Both drugs are legitimate, widely prescribed medications, and both are widely misused, often alongside opioids. For pain management practices, addiction treatment programs, and the distributors that supply them, that combination (common prescription, common misuse, invisible to a standard screen) is exactly why urine drug monitoring protocols increasingly need to go beyond the base panel. This guide covers why the standard panel misses both drugs, what specialty testing exists, why programs test for them, and where gabapentin's patchwork state scheduling status currently stands.
Why a Standard Opiate Panel Does Not Catch Tramadol
Immunoassay opiate screens work by exposing a urine sample to antibodies designed to bind to a specific chemical target, in this case morphine and its closest relatives. A cross reactivity reference maintained by Oregon Health and Science University's Department of Pathology catalogs which compounds trigger a positive on each standard immunoassay class. Morphine, codeine, hydrocodone, oxycodone, dihydrocodeine, ethylmorphine, and 6 acetylmorphine (a heroin metabolite) all register as opiate positive. Tramadol does not appear on that list as an opiate cross reactant, because although it is a weak opioid receptor agonist, its molecular structure falls outside what the standard antibody recognizes.
The practical result: a patient prescribed tramadol for pain, or a person misusing it, can test negative on a standard opiate strip every time. Laboratories that study urine drug monitoring in pain patients have found similar detection gaps with other non-morphine-class analgesics and have pushed for expanded testing methods, including liquid chromatography paired with tandem mass spectrometry (LC-MS/MS), specifically to close these gaps in compliance monitoring programs.
Gabapentin Is Not an Opioid, So It Was Never on the Panel
Gabapentin is an anticonvulsant, prescribed for nerve pain, seizures, and increasingly as an off-label adjunct in pain management. It has no chemical relationship to morphine, codeine, or any opiate, so no standard 5, 10, or 12 panel opiate strip was ever designed to detect it. Detecting gabapentin requires either a dedicated gabapentinoid immunoassay or a validated LC-MS/MS laboratory assay built specifically to identify and quantify it, the same approach researchers have used to study how common gabapentin and pregabalin use actually is among chronic pain patients being monitored.
Why This Gap Matters for Pain Management and Treatment Programs
Gabapentin has become what researchers studying its misuse describe as an opportunistic drug of abuse, largely because it is inexpensive and, at the federal level, not a controlled substance. The clinical concern is specific: gabapentin is frequently combined with opioids to intensify the opioid effect. A peer-reviewed review of gabapentin misuse and the opioid epidemic found that about 24 percent of patients with sustained co-prescription of gabapentin and opioids had at least three prescription claims exceeding recommended dosage thresholds, compared with only 3 percent and 8 percent among patients using just one of the two drugs. The same review found that combining gabapentin and opioids carries roughly a fourfold increase in the risk of respiratory depression, the primary mechanism behind opioid overdose death. At gabapentin doses above 900 milligrams taken with opioids, the same research links the combination to an estimated 60 percent increase in opioid-related death risk.
That is precisely why a pain clinic monitoring a patient on opioid therapy, or a treatment program monitoring someone in recovery, cannot treat a negative standard panel as reassurance. A patient could be taking tramadol on top of a prescribed regimen, or combining gabapentin with opioids in a way that meaningfully raises overdose risk, and a standard cup would show nothing.
Gabapentin's Scheduling Status Is Also a State by State Patchwork
At the federal level, gabapentin is not a controlled substance under the Controlled Substances Act. States have responded individually. A jurisdiction-by-jurisdiction analysis published in the peer-reviewed literature found that eight states have classified gabapentin as a Schedule V controlled substance since Kentucky became the first to do so in July 2017, with West Virginia and Tennessee following in 2018, and additional states adopting similar rules in the years after. Kentucky's own administrative regulation states plainly that the Cabinet for Health and Family Services designates gabapentin as a Schedule V controlled substance in that state. The same analysis found a larger group of states, seventeen in total, require gabapentin prescriptions to be reported to a state prescription drug monitoring program without formally scheduling the drug.
Because this list changes as legislatures act, and because scheduling status affects everything from refill limits to how a positive result should be handled internally, buyers should confirm the current rule in their own state directly rather than relying on any fixed list, including this one.
How to Actually Test for Tramadol and Gabapentin
| Test type | Detects tramadol | Detects gabapentin | Best use |
|---|---|---|---|
| Standard 5, 10, or 12 panel opiate screen | No | No | General workplace and DOT-style programs where neither drug is a stated concern |
| Tramadol-specific immunoassay | Screens presumptively, yes | No | Pain programs monitoring tramadol adherence or misuse |
| Gabapentinoid-specific immunoassay | No | Screens presumptively, yes | Pain and treatment programs monitoring gabapentin or pregabalin use |
| Laboratory confirmation (LC-MS/MS) | Confirms and quantifies, yes | Confirms and quantifies, yes | Confirming any non-negative specialty screen before it affects care or program status |
ASC's pain management and pain clinic drug testing collection and rehabilitation and addiction treatment center drug testing collection are built for exactly this kind of expanded monitoring, with multi-panel cups from the drug testing cups collection serving as a base panel that a program layers additional analytes onto. Confirmation of any non-negative result runs through the laboratory and reference lab drug testing supplies collection.
Building a Defensible Monitoring Protocol
- Start from an accurate baseline. Assume a standard opiate panel says nothing about tramadol or gabapentin use, because it does not.
- Match the panel to the population. Pain clinics prescribing either drug and treatment programs monitoring recovery from opioid use disorder are the two groups most likely to need dedicated screening.
- Confirm before acting. Any non-negative specialty result needs laboratory confirmation, exactly as ASC's guide to what lab confirmation does after a non-negative screen describes for any other analyte.
- Track state scheduling separately from testing. Gabapentin's Schedule V status in some states affects prescribing and refill rules independent of what a drug test shows, and ASC's guide to how pain clinics stay DEA compliant covers how testing protocols fit into that broader compliance picture.
- Document the source for every legal claim. Cite the current state statute or regulation directly when a policy depends on a specific state's scheduling decision.
Frequently Asked Questions
Does tramadol show up on a standard opiate drug test?
No, not reliably. Standard opiate immunoassay panels are built to detect morphine, codeine, and closely related compounds like hydrocodone and oxycodone. Tramadol's chemical structure differs enough from that group that it does not consistently trigger a positive opiate result on a standard 5, 10, or 12 panel screen.
Does gabapentin show up on a standard drug test?
No. Gabapentin is not an opioid and has no chemical relationship to the compounds standard opiate panels target, so it was never included in routine 5, 10, or 12 panel drug testing. Detecting it requires a dedicated gabapentinoid immunoassay or laboratory confirmation.
Why do pain clinics test for tramadol and gabapentin specifically?
Both drugs are commonly prescribed for pain and commonly misused, often together with opioids. Research on gabapentin misuse links co-use with opioids to roughly a fourfold increase in respiratory depression risk and an estimated 60 percent increase in opioid-related death risk at higher gabapentin doses, which is why programs monitoring opioid therapy add dedicated testing for both drugs.
Is gabapentin a controlled substance?
Not at the federal level. Several states have independently classified gabapentin as a Schedule V controlled substance, starting with Kentucky in 2017, while a larger group of states require gabapentin prescriptions to be reported to a prescription drug monitoring program without formally scheduling it. The current rule varies by state and should be confirmed directly.
What test actually detects tramadol or gabapentin?
A dedicated tramadol-specific or gabapentinoid-specific immunoassay screens presumptively for each drug. Any non-negative result should then be confirmed with a laboratory LC-MS/MS assay, which identifies and quantifies the specific compound present.
Does a non-negative tramadol or gabapentin screen mean a patient tested positive?
No. A non-negative immunoassay result is presumptive only. It must be confirmed by laboratory testing before it is treated as a positive result or used in any clinical, employment, or program decision.
Compliance and Accuracy Note
Drug test cups, dip cards, and immunoassay screening devices provide presumptive screening results, not a diagnosis. Any non-negative screening result should be treated as preliminary and confirmed through laboratory testing before any clinical, employment, or legal action is taken. This article is informational only and is not legal or medical advice; verify current federal and state law, and consult qualified counsel, before implementing a testing or prescribing policy.
